Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | AKT1 | P31749 | 2/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14683175 | 0.89 | PDE4B (0.36) | PDE4BAKT1NOTUMMAPK14MAPK11 | |
| Hydrochloric Acid SCHEMBL2351254 | 0.89 | AKT1 (0.42) | PDE4BAKT1NOTUMPROKR1 | |
| SCHEMBL14683184 | 0.88 | NOTUM (0.36) | PDE4BAKT1NOTUMMAPK14MAPK11 | |
| SCHEMBL1689732 | 0.84 | NOTUM (0.51) | AKT1NOTUMPROKR1 | |
| SCHEMBL14683188 | 0.82 | SMN1; SMN2 (0.36) | — | |
| SCHEMBL15772145 | 0.82 | SMN1; SMN2 (0.36) | — | |
| SCHEMBL10253494 | 0.81 | NOTUM (0.44) | PDE4BAKT1NOTUM | |
| SCHEMBL15772672 | 0.80 | SMN1; SMN2 (0.41) | — | |
| SCHEMBL15771957 | 0.80 | DRD2 (0.35) | NOTUMPROKR1 | |
| SCHEMBL14683218 | 0.80 | SMN1; SMN2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2739626-B1 | NOVEL SPIROINDOLINE COMPOUNDS | INTERVET INT BV (NL) | 2016-05-04 | — | — | EP | disclosed |
| US-9096599-B2 | Spiroindoline compounds | INTERVET INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140163056-A1 | NOVEL SPIROINDOLINE COMPOUNDS | INTERVET INC. | 2014-06-12 | — | — | US | disclosed |
| EP-2739626-A1 | NOVEL SPIROINDOLINE COMPOUNDS | Intervet International B.V. (NL) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013017678-A1 | NOVEL SPIROINDOLINE COMPOUNDS | INTERVET INTERNATIONAL B.V. (NL) | 2013-02-07 | — | — | WO | disclosed |
| WO-2013017678-A1 | NOVEL SPIROINDOLINE COMPOUNDS | INTERVET INTERNATIONAL B.V. (NL) | 2013-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163056-A1 | NOVEL SPIROINDOLINE COMPOUNDS | PKD2, PKD1, REN | PDE4B 218/4885AKT1 3154/4885NOTUM 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.